Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Omecamtiv Mecarbil in Healthy Chinese Subjects
Omecamtiv mecarbil was well tolerated at the dose levels of 25-50 mg in healthy Chinese participants according to a pharmacokinetic-based titration scheme. Exposure of omecamtiv mecarbil was dose proportional, and no dose-related trends were observed in treatment-emergent adverse events.
Authors
- Hanjing Chen (ORCID: https://orcid.org/0000-0002-2136-2807)
- Chao Liu (ORCID: https://orcid.org/0000-0001-5410-5519)
- Lei Sheng (ORCID: https://orcid.org/0000-0002-5784-076X)
- Mengjie Yang (ORCID: https://orcid.org/0000-0001-7683-1888)
- Jing Li (ORCID: https://orcid.org/0000-0002-2271-7761)
- Hui Li (ORCID: https://orcid.org/0000-0002-3039-2813)
- Xuening Li (ORCID: https://orcid.org/0000-0003-3899-5245)
- Fei Yuan (ORCID: https://orcid.org/0000-0002-6355-636X)
- Hongrong Xu
Institutions
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
Publication Details
- Journal
- Drugs in R&D
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1007/s40268-025-00532-7
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen